ARF-dependent regulation of ATM and p53 associated KZNF (Apak) protein activity in response to oncogenic stress

The KRAB-type zinc-finger protein Apak (ATM and p53 associated KZNF protein) specifically suppresses p53-mediated apoptosis. Upon DNA damage, Apak is phosphorylated and inhibited by ATM kinase, resulting in p53 activation. However, how Apak is regulated in response to oncogenic stress remains unknown. Here we show that upon oncogene activation, Apak is inhibited in the tumor suppressor ARF-dependent but ATM-independent manner. Oncogene-induced ARF protein directly interacts with Apak and competes with p53 to bind to Apak, resulting in Apak dissociation from p53. Thus, Apak is differentially regulated in the ARF and ATM-dependent manner in response to oncogenic stress and DNA damage, respectively.

Structured summary

MINT-7989670: p53 (uniprotkb:P04637) binds (MI:0407) to APAK (uniprotkb:Q8TAQ5) by pull down (MI:0096)MINT-7989812: HDM2 (uniprotkb:Q00987) physically interacts (MI:0915) with ARF (uniprotkb:Q8N726-1) by anti bait coimmunoprecipitation (MI:0006)MINT-7989603, MINT-7989626: APAK (uniprotkb:Q8TAQ5) physically interacts (MI:0915) with ARF (uniprotkb:Q8N726-1) by anti bait coimmunoprecipitation (MI:0006)MINT-7989653: ARF (uniprotkb:Q8N726-1) binds (MI:0407) to APAK (uniprotkb:Q8TAQ5) by pull down (MI:0096)MINT-7989686, MINT-7989705, MINT-7989747:APAK (uniprotkb:Q8TAQ5) physically interacts (MI:0915) with ARF (uniprotkb:Q8N726-1) by anti tag coimmunoprecipitation (MI:0007)MINT-7989724: APAK (uniprotkb:Q8TAQ5) physically interacts (MI:0914) with ARF (uniprotkb:Q8N726-1) and p53 (uniprotkb:P04637) by anti tag coimmunoprecipitation (MI:0007)MINT-7989635: ARF (uniprotkb:Q8N726-1) and APAK (uniprotkb:Q8TAQ5) colocalize (MI:0403) by fluorescence microscopy (MI:0416)MINT-7989584, MINT-7989773: APAK (uniprotkb:Q8TAQ5) physically interacts (MI:0915) with p53 (uniprotkb:P04637) by anti tag coimmunoprecipitation (MI:0007)     

The magnitude of methylmercury-induced cytotoxicity and cell cycle arrest is p53-dependent

BACKGROUND: Methylmercury (MeHg), a ubiquitous environmental contaminant, is a known potent teratogen selectively affecting the developing central nervous system. While a definitive mechanism for MeHg-induced developmental neurotoxicity remains elusive, in utero exposure has been associated with reduced brain weight and reduction in cell number. This suggests early toxicant interference with critical molecular signaling events controlling cell behavior, i.e., proliferation. METHODS: To examine the role of p53, a major regulator of the G(1)/S and G(2)/M cell cycle checkpoints, in MeHg toxicity, we isolated GD 14 primary embryonal fibroblasts from homozygous wild-type p53 (p53+/+) and homozygous null p53 (p53-/-) mice. Cells were treated at passages 4-7 for 24 or 48 hr with 0, 1.0, or 2.5 microM MeHg and analyzed for effects on viability, cell cycle progression (using BrdU-Hoechst flow cytometric analysis), and apoptosis via annexin V-FITC and propidium iodide (PI) staining. RESULTS: The p53+/+ cells are more sensitive than p53-/- cells to MeHg-induced cytotoxicity, cell cycle inhibition, and induction of apoptosis: at 24 hr, 2.5 microM MeHg reduced p53+/+ cell viability to 72.6% +/- 3.2%, while p53-/- viability was 94.6% +/- 0.4%. The p53-/- cells underwent less necrosis and less apoptosis following MeHg treatment. MeHg (2.5 microM) also halted all cycling in the p53+/+ cells, while 42.6% +/- 7.2% of p53-/- cells were able to reach a new G(0)/G(1) in 48 hr. Time- and dose-dependent accumulation of cells in G(2)/M phase (1.0 and 2.5 microM MeHg) was observed independent of the p53 genotype; however, the magnitude of change was p53-dependent. CONCLUSIONS: These studies suggest that MeHg-induced cell cycle arrest occurs via both p53-dependent and -independent pathways in our model system; however, cell death resulting from MeHg exposure is highly dependent on p53.     

普罗布考对动脉粥样硬化大鼠平滑肌细胞凋亡及p53和Fas蛋白表达的影响

目的探讨普罗布考防治动脉粥样硬化（AS）的机制。方法选用雄性大鼠,复制大鼠AS模型,随机分为动脉粥样硬化模型组、普罗布考组和正常对照组。大鼠造模成功后给予普罗布考治疗,6周后处死大鼠,采用流式细胞术检测平滑肌细胞凋亡率及凋亡相关基因p53和Fas蛋白的表达。结果模型组大鼠血管平滑肌细胞凋亡率明显高于对照组（P〈0．05）,p53和Fas蛋白的表达增强（P％0．05）,主动脉壁可肉眼观测典型斑块。普罗布考组大鼠平滑肌细胞的凋亡率明显低于模型组（P〈0．05）,p53和Fas蛋白表达下调（P〈0．05）,主动脉斑块面积较模型组减小明显。结论普罗布考通过调节p53和Fas蛋白表达来调节AS大鼠平滑肌细胞的凋亡。     

Biological functions of p53 isoforms through evolution: lessons from animal and cellular models

The TP53 tumour-suppressor gene is expressed as several protein isoforms generated by different mechanisms, including use of alternative promoters, splicing sites and translational initiation sites, that are conserved through evolution and within the TP53 homologues, TP63 and TP73. Although first described in the eighties, the importance of p53 isoforms in regulating the suppressive functions of p53 has only become evident in the last 10 years, by analogy with observations that p63 and p73 isoforms appeared indispensable to fully understand the biological functions of TP63 and TP73. This review summarizes recent advances in the field of 'p53 isoforms', including new data on p63 and p73 isoforms. Details of the alternative mechanisms that produce p53 isoforms and cis- and trans-regulators identified are provided. The main focus is on their biological functions (apoptosis, cell cycle, aging and so on) in cellular and animal models, including mouse, zebrafish and Drosophila. Finally, the deregulation of p53 isoform expression in human cancers is reviewed. Based on these latest results, several developments are expected in the future: the identification of drugs modulating p53 isoform expression; the generation of animal models and the evaluation of the use of p53 isoform as biomarkers in human cancers.     

Central and carboxy-terminal regions of human p53 protein are essential for interaction and complex formation with PARP-1

It has been previously described by different groups that poly(ADP-ribose) polymerase-1 (PARP-1) and the product of the tumor suppressor gene p53 form tight complexes. We investigated which domains of human PARP-1 and of human wild-type p53 were involved in this protein-protein interaction. We generated baculoviral constructs encoding full length protein or distinct functional domains of both proteins. Baculovirally expressed wild-type p53 was posttranslationally modified. Full length PARP-1 was simultaneously coexpressed in insect cells with full length wt p53 protein or its distinct truncated fragments and vice versa. Reciprocal immunoprecipitation of Sf9 cell lysates revealed that the central and carboxy-terminal fragments of p53 were sufficient to confer binding to PARP-1. The amino-terminal part harboring the transactivation functional domain of p53 was dispensable. On the other hand, the amino-terminal and central fragments of PARP-1 were necessary for complex formation with p53 protein. Finally, we explored the functional significance of the interaction between both proteins. Inactivation of PARP-1 resulted in the reduction of p53 steady-state levels. Inhibition of nuclear export by leptomycin B prevented accelerated degradation of p53 in PARP-1 KO cells and led to accumulation of p53 protein. Considering the fact that the accelerated p53 nuclear export in the absence of PARP-1 contributes to enhanced p53 degradation, we conclude that PARP-1 may mask the NES of p53 through complex formation with its carboxy-terminal part, thereby preventing the export.     

p53基因表达沉默的稳定Vero细胞系的建立及特性分析

利用慢病毒介导的RNA干扰技术,建立稳定沉默p53基因的Vero细胞模型。设计针对p53基因的shRNA序列,构建p53shRNA慢病毒载体并感染Vero细胞;嘌呤霉素筛选阳性细胞,局部消化法挑选细胞克隆;利用RT-PCR和West-ernblot检测p53的表达水平;利用虫荧光素酶报告系统,分析p53的转录激活功能。RT-PCR和Westernblot结果显示,慢病毒介导的shRNA有效地沉默p53基因表达;与对照组细胞相比,干扰组细胞的p53的转录激活功能明显降低。慢病毒介导的shRNA高效、稳定地沉默了p53基因的表达,同时,有效地降低了p53的转录激活功能,为研究p53的生物学功能提供了有利的工具。     

PML与基因组稳定性

基因组稳定性同肿瘤的发生、发展密切相关,维护基因组稳定性对于细胞行使正常的生理功能是至关重要的.早幼粒细胞白血病蛋白PML(promyelocytic leukemia)主要借助分子中RBCC结构,同近50种有重要功能的蛋白相互作用而形成PML-NBs(PML nuclear bodies).PML-NBs是与核基质结合的、动态的、亚核多蛋白复合物,它作为区室化核结构(compartmentalized nuclear architecture)——染色质间区室(interchromatin compartment)的功能单位,满足了真核基因高层次表达调控模式的时空要求.最新的研究证明：PML是基因组稳定性“守门人”——p53分子的搭档分子,同样在基因组稳定性调控中发挥着重要的功能作用.它协同p53参与了DNA损伤反应所诱发的细胞凋亡,还可组织多种DNA修复分子参与DNA损伤修复,在DNA损伤反应中具有重要作用;此外,PML还通过调控aurora A的活性参与中心体复制检查点调控,借助调控survivin的表达参与有丝分裂纺锤体组装检查点调控,在染色体复制和细胞分裂中均显示了重要的调控作用.而当PML表达缺失或不足时则与多种肿瘤的发生、发展相关联,因此PML分子在维护基因组稳定性中具有重要功能作用,本文仅就相关的最新研究进展予以概述     

低氧微环境中肿瘤的能量代谢

处于低氧微环境中的肿瘤细胞,其血管生成和代谢方式的改变使之能在低氧环境中生存及增殖。Warburg早已发现肿瘤细胞的代谢方式的改变．即在有氧环境中也优先利用糖酵解而非有氧呼吸来获得能量。与有氧呼吸有关的酶,如COX、SDH、FH,发生改变及抑癌基因p53的突变与其发生机制有关。     

Cancer‐specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis

Wild‐type p53 functions as a tumour suppressor while mutant p53 possesses oncogenic potential. Until now it remains unclear how a single mutation can transform p53 into a functionally distinct gene harbouring a new set of original cellular roles. Here we show that the most common p53 cancer mutants express a larger number and higher levels of shorter p53 protein isoforms that are translated from the mutated full‐length p53 mRNA. Cells expressing mutant p53 exhibit “gain‐of‐function” cancer phenotypes, such as enhanced cell survival, proliferation, invasion and adhesion, altered mammary tissue architecture and invasive cell structures. Interestingly, Δ160p53‐overexpressing cells behave in a similar manner. In contrast, an exogenous or endogenous mutant p53 that fails to express Δ160p53 due to specific mutations or antisense knock‐down loses pro‐oncogenic potential. Our data support a model in which “gain‐of‐function” phenotypes induced by p53 mutations depend on the shorter p53 isoforms. As a conserved wild‐type isoform, Δ160p53 has evolved during millions of years. We thus provide a rational explanation for the origin of the tumour‐promoting functions of p53 mutations.     

藤黄新酸抑制肝癌细胞生长的机制研究

在肿瘤细胞中蛋白酶体活性的抑制可以导致细胞凋亡和周期阻滞.藤黄新酸(TH2)是从中药藤黄中提取的一个新的(口山)酮类衍生物.研究结果显示,TH2可以抑制人肝癌Bel-7402细胞的增殖,诱导细胞产生凋亡,且呈浓度和时间依赖性.同时,10μmol/L的TH2与细胞作用24h后,可以导致早期凋亡标志性蛋白PARP发生裂解.在体外采用特异性荧光底物检测TH2对蛋白酶体活性的影响,发现该化合物能够抑制蛋白酶体的糜乳蛋白酶样、胰蛋白酶样活性和谷氨酰后水解活性.抑癌基因p53是细胞内的蛋白酶体降解底物,TH2可使p53蛋白的降解受到阻滞,表达增加.由此可见,TH2具有抑制人肝癌Bel-7402细胞增殖、诱导细胞凋亡的作用,可能的分子机制与其抑制细胞内蛋白酶体活性、导致p53蛋白降解受阻有关.     

miR-34家族——-肿瘤抑制蛋白p53高度相关microRNA

若干微小RNA(microRNA, miRNA)与肿瘤抑制蛋白p53高度相关, 其中miR-34家族最具代表性。一方面p53可通过对miR-34家族的调控实现对多个原癌基因如Bcl-2、c-myc以及细胞因子如cyclinE2、cyclinD1和c-Met的抑制, 进而发挥抑癌作用; 另一方面miR-34家族也可以通过抑制沉默信息调节子SIRTI来进一步增强p53的活性。p53与miR-34家族之间形成的正反馈调节网络对抑制肿瘤的发生发展及恶化均起着重要的作用。文章对p53高度相关的miR-34家族在肿瘤发生发展及治疗的最新进展作一论述。     

突变体p53研究进展

抑癌基因突变是癌症发生过程中一个极为关键的事件。p53作为体内最重要的抑癌基因之一, 在人类癌症中发生突变的频率高达50%。同时, p53突变也是人类遗传病Li-Fraumeni综合征的主要病因。p53最常见的突变形式是错义突变, 所形成的突变体p53不但失去了野生型p53的抑癌功能, 而且还获得了一系列类似于癌基因的功能, 促进了肿瘤的进程。文章拟对突变体p53的结构功能改变, 获得癌基因活性的分子机制, 以及近年来对封闭突变体p53活性所进行的探索等研究方向所取得的进展做一综述。     

p53转录非依赖活性介导细胞凋亡

p53主要通过两条途径诱导细胞凋亡：p53作为转录因子,促进细胞凋亡的靶基因的表达上调,如PUMA、NOXA、PIDD、p53AIP1、COP1等,并通过这些蛋白参与内源和外源凋亡途径;另一方面,胞浆中的p53能转位到线粒体,激活内源性的线粒体途径,促进凋亡。后者已成为研究p53促凋亡机制的热点。本文就p53对转录非依赖活性诱导细胞凋亡途径的研究进展作一概述。     

H1N1亚型流感病毒诱导外周血单个核细胞凋亡研究

A型流感病毒能诱导淋巴细胞、单核巨噬细胞的凋亡,为进一步探讨淋巴细胞和单核巨噬细胞在凋亡中可能存在的相互作用,用H1N1亚型流感病毒诱导人外周血淋巴细胞和单核巨噬细胞的凋亡．结果显示,前48 h,H1N1流感病毒能诱导淋巴细胞和单核巨噬细胞的凋亡,但在培养48 h后,流感病毒对单核巨噬细胞表现为凋亡抑制作用,同时流感病毒对淋巴细胞吸附不同时间后,荧光染色和流式细胞术检测凋亡未见明显差异,说明细胞凋亡与病毒吸附时间长短并无相关性．检测p53抑制剂Pifithrin-α(PFT-α)加入前后淋巴细胞和单核巨噬细胞的凋亡情况,结果显示,淋巴细胞和单核巨噬细胞的凋亡均被抑制, 提示通过p53诱导的凋亡可能是流感病毒诱导细胞凋亡的一条重要途径．     

应用免疫-PCR检测癌症的初步研究

探索一种简便、灵敏度高、特异性强且易推广的血清中突变型ｐ５３蛋白检测方法,用于肿瘤早期诊断。用突变型ｐ５３蛋白的单克隆抗体,与特定ＤＮＡ片段连接制成基因探针,用免疫－ＰＣＲ技术,对１１７例病人血清样品进行检测。在１１７例病人血清样品中,检测总阳性率为４１．８８％（４９／１１７）,在临床怀疑为癌症及肿瘤病人中阳性率达５２．１１％（３７／７１）。     

DNA双链断裂损伤反应及它的医学意义

DNA损伤应激反应是维持基因组稳定性的基石.细胞在长期进化中形成了由损伤监视、周期调控、损伤修复、凋亡诱导等在内的自稳平衡机制.一方面,借助感应、识别并启动精细而复杂的修复机制修复损伤;另一方面,通过DNA损伤应激活化的细胞周期检查点机制,延迟或阻断细胞周期进程,为损伤修复提供时间,使细胞能安全进入新一轮细胞周期;损伤无法修复时则诱导细胞凋亡.DNA双链断裂(double strand breaks,DSBs)是真核基因组后果最严重的损伤类型之一,其修复不利,同肿瘤等人类疾病的发生发展密切相关.新进展揭示:DSBs损伤反应信号分子ATM-Chk2-p53、H2AX等的组成性活化,是肿瘤形成早期所激活的细胞内可诱导的抗癌屏障,其信号网络的精确、精细调控在基因组稳定性维持中发挥重要作用.此外,HIV病毒整合进入宿主细胞基因组的过程也依赖于宿主细胞中ATM介导的DSBs损伤反应信号转导;ATM特异性的小分子抑制剂在抗HIV感染中显示重要的功能意义.文中重点讨论调控DSBs损伤应激反应信号网络的主要研究进展,及其在肿瘤发生、发展及抗HIV感染中的新医学意义.     

蛋白激酶CK2-β及其相关的p53在涎腺腺样囊性癌中的表达及意义

目的　通过对蛋白激酶CK2 β (proteinkinaseCK2 β)及 p5 3蛋白在涎腺腺样囊性癌 (salivaryadenoidcysticcarcinoma ,SACC)中表达分布特征的研究 ,探讨其在该肿瘤发生发展中的作用及临床病理意义。方法　应用免疫组化技术检测 45例SACC及 12例正常涎腺组织中蛋白激酶CK2 β及 p5 3的表达变化。结果　SACC标本中蛋白激酶CK2 β阳性 37例 ,阴性 8例 ;正常腺体组织中蛋白激酶CK2 β阳性 2例 ,阴性 10例 (P <0 0 1) ;p5 3在SACC标本中阳性 6例 ,阴性 39例。二者的表达在病理学各分型及临床各分期之间无显著差异 (P >0 0 5 )。结论　蛋白激酶CK2 β在SACC组织中呈高表达 ,与其相关的 p5 3在SACC中呈低表达。但二者与SACC病理学分型及临床分期无关。